ReviewLife (Basel, Switzerland)2025
Association Between Lycopene and Metabolic Disease Risk and Mortality: Systematic Review and Meta-Analysis.
Review in Life (Basel, Switzerland), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Review
- Next-Generation Hydrogels Integrating Natural Antioxidants and Microbiome Modulators for Improved Cancer Management.Gels (Basel, Switzerland) · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundLycopene, a dietary carotenoid with antioxidant properties, protects against sun-induced skin damage, prostatic conditions such as chronic prostatitis, and cancer; however, its role in metabolic disorders, including metabolic syndrome and nonalcoholic fatty liver disease (MAFLD), remains unclear. This study aimed to systematically assess the association between lycopene levels (serum and dietary) and the risk of metabolic diseases.
methodsThis study adhered to the PRISMA guidelines and was prospectively registered on the Open Science Framework (OSF). We searched PubMed, Scopus, Web of Science, and Medline via WoS. Pooled odds ratios (OR), hazard ratios (HR), and mean differences (MD) with 95% confidence intervals (CIs) were calculated using fixed or random-effects models based on heterogeneity.
resultsTwenty-nine studies were included, of which twenty-five were eligible for the meta-analysis. Pooled analysis showed that the individuals with the lowest serum lycopene levels had a significantly higher risk of MAFLD (OR = 1.39, 95%CI: 1.02-1.89,
conclusionsWhile lower serum lycopene levels are significantly associated with increased MAFLD risk, their impact on glycemic control remains inconclusive, underscoring the need for targeted clinical research.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.